Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications.

[1]  E. Topol,et al.  Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. , 1996, American heart journal.

[2]  R. Califf,et al.  Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). , 1995, Journal of the American College of Cardiology.

[3]  R. Califf,et al.  A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. CAVEAT-II Investigators. , 1995, Circulation.

[4]  P. Yock,et al.  730-2 Acute Angiographic, Intravascular Ultrasound and Clinical Results of Directional Atherectomy in the Optimal Atherectomy Restenosis Study , 1995 .

[5]  D. Baim,et al.  Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. , 1994, The American journal of cardiology.

[6]  V. Fuster,et al.  Effect of an Eccentric Severe Stenosis on Fibrin(ogen) Deposition on Severely Damaged Vessel Wall in Arterial Thrombosis: Relative Contribution of Fibrin(ogen) and Platelets , 1994, Circulation.

[7]  D. Altieri,et al.  Differential ligand binding specificities of recombinant CD11b/CD18 integrin I-domain. , 1994, The Journal of biological chemistry.

[8]  V. Fuster,et al.  Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. , 1994, Journal of the American College of Cardiology.

[9]  R. Califf,et al.  Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months , 1994, The Lancet.

[10]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[11]  D. Baim,et al.  Complications of directional coronary atherectomy: incidence, causes, and management. , 1993, The American journal of cardiology.

[12]  M. Cowley,et al.  Experience with directional coronary atherectomy since pre-market approval. , 1993, The American journal of cardiology.

[13]  E. Topol,et al.  Results of directional coronary atherectomy during multicenter preapproval testing. The US Directional Coronary Atherectomy Investigator Group. , 1993, The American journal of cardiology.

[14]  D. Ricci,et al.  A comparison of directional atherectomy with balloon angioplasty for lesions of the left anterior descending coronary artery. , 1993, The New England journal of medicine.

[15]  R. Califf,et al.  A Comparison of Directional Atherectomy with Coronary Angioplasty in Patients with Coronary Artery Disease , 1993 .

[16]  S. Schnitt,et al.  Long-term results of directional coronary atherectomy: predictors of restenosis. , 1992, Journal of the American College of Cardiology.

[17]  M. Bell,et al.  Results of directional atherectomy of primary atheromatous and restenosis lesions in coronary arteries and saphenous vein grafts. , 1992, The American journal of cardiology.

[18]  E. Topol,et al.  Abrupt vessel closure after directional coronary atherectomy , 1992 .

[19]  J. Simpson,et al.  Effect of lesion characteristics on outcome of directional coronary atherectomy. , 1991, Journal of the American College of Cardiology.

[20]  L. Klein,et al.  Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty. , 1991, Journal of the American College of Cardiology.

[21]  E J Topol,et al.  Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. , 1990, Circulation.

[22]  R D Safian,et al.  Coronary atherectomy. Clinical, angiographic, and histological findings and observations regarding potential mechanisms. , 1990, Circulation.

[23]  V. Fuster,et al.  Platelet thrombus formation on collagen type I. A model of deep vessel injury. Influence of blood rheology, von Willebrand factor, and blood coagulation. , 1988, Circulation.

[24]  P. Mannucci,et al.  Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen , 1988, The Journal of cell biology.

[25]  A. Jaffe,et al.  Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase , 1988 .

[26]  A. Jaffe,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. , 1988, Journal of the American College of Cardiology.

[27]  I. Charo,et al.  Platelet glycoprotein IIb-IIIa-like proteins mediate endothelial cell attachment to adhesive proteins and the extracellular matrix. , 1987, The Journal of biological chemistry.

[28]  J. Oh,et al.  Creatine kinase release after successful percutaneous transluminal coronary angioplasty. , 1985, American heart journal.